Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | GLA | P06280 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 4/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.74 |
| ▸ | CDK4 | P11802 | 4/20 | 0.69 |
| ▸ | CCND1 | P24385 | 4/20 | 0.69 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | AANAT | Q16613 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13942340 | 0.89 | MEN1 (0.81) | MEN1KMT2AALDH1A1GLANPC1 | |
| SCHEMBL797879 | 0.86 | MEN1 (0.76) | MEN1KMT2AALDH1A1GLANPC1 | |
| SCHEMBL4331421 | 0.85 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9ACDK4 | |
| SCHEMBL1518173 | 0.84 | MEN1 (0.69) | MEN1KMT2AALDH1A1GLANPC1 | |
| Cyanide SCHEMBL31484737 | 0.82 | MEN1 (0.92) | MEN1KMT2ANPC1RAB9ACDK4 | |
| SCHEMBL15047821 | 0.82 | MEN1 (0.82) | MEN1KMT2ANPC1RAB9ACDK4 | |
| SCHEMBL15145341 | 0.82 | PTGS1 (0.76) | MEN1KMT2AALDH1A1GLANPC1 | |
| SCHEMBL15145365 | 0.82 | PTGS1 (0.79) | MEN1KMT2AALDH1A1GLANPC1 | |
| SCHEMBL4492489 | 0.82 | TRPV1 (0.83) | MEN1KMT2ANPC1RAB9ACDK4 | |
| SCHEMBL7866515 | 0.81 | MEN1 (0.73) | MEN1KMT2ANPC1RAB9ACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | disclosed |
| WO-2021211123-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | TLR4, TLR5, TLR1 | MEN1 2778/4885KMT2A 2581/4885ALDH1A1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.